NanoMab appoints Paul Edwards as CEO and sets up in UK in preparation for  European clinical trial programme

Precision oncology therapeutics company moves centre of operations from China

London, April 28, 2020: NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies via the development of next generation radiopharmaceuticals, today announced a number of key management changes. The company has also established a UK subsidiary office and moved its centre of operations as it prepares to start clinical trials for its camelid antibody therapeutics and imaging agents in Q4 2020.

Paul Edwards MBE has been appointed as Chief Executive Officer and will be joined by Robin Pakenham as Director of Finance and Operations. In addition, Ian Miscampbell will join the Board as a non-Executive Director.

Dr. Hong Hoi Ting, the co-founder of the company becomes the Executive Chair as well as the Chief Scientific Officer.

Paul Edwards commented: “I am delighted to join NanoMab at this exciting stage of the company’s development. The founding team’s world-class expertise in radiopharmaceuticals has enabled development of an innovative pipeline of precision theranostics, combining imaging agents with therapeutics. The first candidates have already completed FIH studies and are now ready to be taken into clinic in the UK and Germany. Strong existing academic links and collaborations, combined with the comprehensive network of experienced trial sites, have made this strategic move to Europe a logical choice.”

 

For more information:

Paul Edwards

Email:  p.m.edwards@nano-mab.com

Media

Richard Hayhurst/Janet Joy RHApr

Tel: +44 (0)7711 821 527

richard@rhapr.eu or jan@rhapr.eu

 

Paul Edwards MBE – Chief Executive Officer

A graduate chemist, Paul initially worked for Beecham Pharmaceuticals and Genzyme Corporation, where he headed the UK operations for the company. In 2000, he joined the UK based biosimilars’ organisation, GeneMedix plc as Chief Executive Officer, and successfully led a major funding round taking the company to a dual listing on the London and Singapore Stock Exchanges. More recently, Paul has acted as a NED to Goldshield Group plc and BioProducts Laboratories and oversaw the sale of both organisations to Private Equity Groups, as well as serving as Managing Partner and board member of the global Executive Search Group, Horton International.

Paul is a familiar face in the UK biotech arena, having been the Chairman of the UK BioIndustry Association’s Manufacturing Advisory Committee and was the recipient of the Donald Medal for services to Biochemical Engineering (1999). In 1997 he received an MBE for services to biotechnology.

 

Robin Pakenham – Finance and Operations Director

After graduating in Engineering Mathematics, Robin trained with KPMG as a Chartered Accountant, leaving in 1992. He then spent 9 years at Legal & General Ventures, one the largest European LBO/PE Investors of the 1990s. In the last 10 years, Robin has been a high impact interim and start-up CFO delivering value in Corporate Finance-rich situations, including: PYReco raising £100m, the sale of BioProducts Laboratory to Bain Capital for £230m, and CP Electronics acquisition by Legrand for £75m.  In 2019, he was CFO of Kind Consumer, as it raised £14m of equity in two rounds prior to the launch of the medically licenced nicotine inhaler, Voke.

 

Dr. Hong Hoi Ting – Executive Chair and Chief Scientific Officer

Dr. Ting is a scientist, entrepreneur and angel investor. He has extensive experience in the Chinese healthcare sector, in particular in nuclear medicine. Most recently, he served as CEO and co-founder of Oxford Vacmedix and Biovue Ltd. He was also the founder of Genemedix Plc., a UK listed biotechnology company. Earlier in his career, he was the China General Manager of Amersham International Plc. and worked as a consultant for Westinghouse Electric, J&J and GE Healthcare. Dr. Ting received his academic training and DPhil degree in biochemistry from the University of Oxford.

 

Ian Miscampbell – Non-Executive Director

Ian has served as Chief Finance Officer and as Chief Operating Officer in a number of publicly quoted and privately-owned healthcare and drug development companies, including Reneuron, KS Biomedix, Microscience, Oxford Immunotec, William Ransom and York Pharma. He was responsible for numerous M&A and licensing transactions and has completed a dozen financing and re-financing transactions, successfully raising in excess of £100m in equity, debt and grant finance. Having spent a short period working as Finance Director in a healthcare fund management business, Ian left in 2010 to establish Sixth Element Capital, a fund management business which runs the CRT Pioneer Fund, a £70 million oncology specialist investment fund. Ian was appointed a Fellow of the Institute of Chartered Accountants in England and Wales in 2011.